Immunovia announces determined exercise price for warrants series TO 3
Rhea-AI Summary
Immunovia AB has announced the exercise price for its warrants series TO 3 at SEK 0.24 per share. The exercise period runs from April 1-15, 2025, with trading available until April 11, 2025. The warrants were issued as part of a Rights Issue in August-September 2024, where each unit consisted of two shares, two TO 2 warrants, and one TO 3 warrant.
If all 62,211,989 warrants are exercised, Immunovia will raise approximately SEK 14.9 million before costs. The subscription price was set at 70% of the volume-weighted average price during March 14-27, 2025. Upon full exercise, the company's share capital will increase by SEK 1,866,359.67 to SEK 9,723,625.56, with total outstanding shares rising from 261,908,863 to 324,120,852, representing a dilution of approximately 19.2%.
Positive
- Potential to raise SEK 14.9 million in additional capital
Negative
- 19.2% shareholder dilution upon full warrant exercise
- Low warrant exercise price of SEK 0.24 indicates weak share price performance
Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the Rights Issue consisted of two (2) shares, two (2) warrants series TO 2 and one (1) warrant series TO 3. One (1) warrant series TO 3 entitles the holder to subscribe for one (1) new share in the Company. If all warrants are exercised, Immunovia will receive approximately
The subscription price for the warrants was set at 70 percent of the volume-weighted average price for the Company's share on Nasdaq Stockholm during the period 14 – 27 March 2025, however not more than an amount corresponding to 150 percent of the subscription price per share in the Rights Issue (
Summary of instructions and important dates
Holders of warrants who wish to exercise these to subscribe for shares shall give notice regarding such exercise at the latest on 15 April 2025. Warrants that have not been exercised on or before 15 April 2025 expire without value. Holders who do not wish to exercise their warrants may sell them. Trading with warrants is ongoing up to and including 11 April 2025.
Detailed information and instructions for subscription
Exercise of nominee-registered warrants
Holders of warrants who have their holdings nominee-registered (holdings in securities custody services, investment savings accounts (ISK) or endowment insurances) must notify the exercise of warrants by contacting their respective nominee and follow the nominee's instructions regarding subscription and payment. This should take place well before 15 April 2025 as different nominees have different processing times.
Exercise of directly registered warrants
Holders of warrants who have their holdings directly registered (holdings on a VP account) must notify the exercise of warrants by filling in and submitting an application form for the exercise, so that the application form is received by the issuing agent, Vator Securities AB, no later than 15 April 2025.
The application form is available on the Company's and Vator Securities AB's respective websites (www.immunovia.com and www.vatorsecurities.se). Please note that payment for the new shares must be received by Vator Securities no later than 15 April 2025 in accordance with the instructions on the application form.
Trading in TO 3
Holders who do not wish to exercise their warrants may sell them on Nasdaq Stockholm. The warrants are traded up to and including 11 April 2025 under the short name IMMNOV TO 3 and with ISIN code SE0022600102. Warrants that are not exercised on 15 April 2025 at the latest will expire without value.
Outcome and delivery of new ordinary shares
The outcome of the exercise of warrants will be published via a press release on or around 17 April 2025. Shares that have been subscribed and paid for may be registered on the subscriber's securities depository as interim shares (IA) until registration of the issue has been completed with the Swedish Companies Registration Office, whereupon the interim shares automatically will be converted into shares in Immunovia.
Change in share capital and number of shares
Upon full exercise of all 62,211,989 warrants series TO 3, the share capital will increase by a maximum of
Complete terms and conditions for the warrants
Complete terms and conditions for the warrants are available on the Company's website, www.immunovia.com.
Advisers
Vator Securities AB acts as financial adviser to Immunovia in connection with the Rights Issue. Setterwalls Advokatbyrå AB is legal adviser to Immunovia in connection with the Rights Issue. Vator Securities AB acts as the issuing agent in connection with the Rights Issue.
For further information, please contact
Jeff Borcherding, CEO
jeff.borcherding@immunovia.com
The information was submitted for publication, through the agency of the contact persons set out above, at 20:40 CET on 27 March 2025.
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
For more information, please visit www.immunovia.com.
IMPORTANT INFORMATION
The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Immunovia. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in Immunovia has only been made through the prospectus published by Immunovia on 12 August 2024. The prospectus has been approved and registered by the Swedish Financial Supervisory Authority and has been published on the Company's website, www.immunovia.com.
Since Immunovia is considered to carry out protection-worthy activities according to the Swedish Screening of Foreign Direct Investments Act (Sw. lag (2023:560) om granskning av utländska direktinvesteringar), the exercise of warrants for subscription of shares may require review by the Inspectorate of Strategic Products (ISP). The Company will, no later than in connection with the commencement of the exercise period for the warrants, publish more information about this on the Company's website, www.immunovia.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press releae (PDF) |
View original content:https://www.prnewswire.com/news-releases/immunovia-announces-determined-exercise-price-for-warrants-series-to-3-302413671.html
SOURCE Immunovia AB
FAQ
What is the exercise price for Immunovia (IMMVF) TO 3 warrants in 2025?
When is the exercise period for Immunovia's TO 3 warrants?
How much capital can Immunovia raise from the TO 3 warrants exercise?
What is the dilution impact of Immunovia's TO 3 warrants on existing shareholders?
How many TO 3 warrants were issued by Immunovia?
